Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).


Clinical Trial Description

The purpose of this study is to evaluate the safety and tolerability of 14 once daily intravenous (IV) infusions of ascending doses of AVI 7537 compared to matched placebo in healthy male and female subjects.

To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01593072
Study type Interventional
Source Sarepta Therapeutics
Contact
Status Withdrawn
Phase Phase 1
Start date August 2012
Completion date January 2013

See also
  Status Clinical Trial Phase
Completed NCT00374309 - Experimental Vaccine for Prevention of Ebola Virus Infection Phase 1
Completed NCT02911415 - Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi N/A
Completed NCT01353027 - Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus Phase 1